Table 4 Univariate and multivariate regression analysis to identify predictors for hepatotoxicity related to erlotinib administration in pancreatic cancer patients
From: Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study
Characteristics | Unadjusted OR (95% CI) | Adjusted OR (95% CI) |
|---|---|---|
Male | 0.957 (0.491–1.865) | 1.279 (0.598–2.737) |
Age ≥ 65 | 0.858 (0.444–1.656) | 0.731 (0.369–1.448) |
BSA ≥ 1.6a | 0.652 (0.336–1.268) | 0.549 (0.255–1.180) |
CYP3A4 Inducer | 3.690 (0.886–15.679) | 4.114 (0.969–17.465) |